Biodesix Inc. (BDSX)
0.81
-0.04 (-4.29%)
At close: Mar 24, 2025, 3:59 PM
0.84
2.88%
After-hours: Mar 24, 2025, 07:56 PM EDT
-4.29% (1D)
| Bid | 0.8 |
| Market Cap | 118.49M |
| Revenue (ttm) | 80.29M |
| Net Income (ttm) | -48.33M |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -2.46 |
| Forward PE | -4.77 |
| Analyst | Buy |
| Ask | 0.87 |
| Volume | 97,662 |
| Avg. Volume (20D) | 437,339 |
| Open | 0.82 |
| Previous Close | 0.85 |
| Day's Range | 0.80 - 0.84 |
| 52-Week Range | 0.64 - 2.04 |
| Beta | 1.10 |
About BDSX
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. ...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 28, 2020
Employees 273
Stock Exchange NASDAQ
Ticker Symbol BDSX
Website https://www.biodesix.com
Analyst Forecast
According to 3 analyst ratings, the average rating for BDSX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 269.59% from the latest price.
Stock Forecasts2 weeks ago
+0.98%
Biodesix shares are trading higher after the compa...
Unlock content with
Pro Subscription
4 months ago
-23.53%
Biodesix shares are trading lower after the company reported worse-than-expected Q3 revenue results. Additionally, the company filed for a $250 million mixed-shelf offering
